Stay updated with breaking news from Structural Heart. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New data from largest head-to-head randomized control TAVR trial demonstrates non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien™ at one year DUBLIN...
New data from largest head-to-head randomized control TAVR trial demonstrates non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien™ at one year
Medtronic (NYSE: MDT) today announced data from a head-to-head trial backing its Evolut TAVR system against the Edwards Sapien platform.
New data from largest head-to-head randomized control TAVR trial demonstrates non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien™ at one year
Debra Wendland, RN recipient of DAISY Nurse Leader Award from HaysMed.